logo

HITAP เข้าสู่ระบบ

ลืมรหัสผ่าน?

The clinical efficacy and economic evaluation of EC-MPS (Myfortic®) in the treatment of relapse or resistant proliferative lupus nephritis. (in Thai language)

Home > Research Projects > Strategy 3 : HTA Research > The clinical efficacy and economic evaluation of EC-MPS (Myfortic®) in the treatment of relapse or resistant proliferative lupus nephritis. (in Thai language)

Project Code

01-338-2552

Research team

Researchers

Adun Mohara B.Pharm, M.Sc.(Health Economic)

Naiyana Praditsitthikorn, PhD.

Co - Researcher

Yingyos Avihingsanon

Yot Teerawattananon, PhD.

Opas Traitanon

Adis Tasanarong

Jeerapat Wongchinsri

Sirirat Reungjui

Anucha Puapairoj

Paskorn Sritipsukho

Wipawee Kittikowit

Project Details

Strategies
Category
Support
Project duration

Start: 8 October 2014
End: 8 October 2014

Contact
[email protected]

Project Status

Conducting Research - 65%

Viewer: 1727

Publish date3 December 2011 01:44

Project Summary

The Clinical Research Collaboration Network in collaboration with the HITAP conducted a clinical test of Randomized Controlled Trial (RCT) regarding the treatment of relapse or resistant proliferative lupus nephritis. The objective of this research was to determine the efficacy of enteric-coated Mycophenolate Sodium combined with corticosteroids for a period of 12 months in patients with relapse or cyclophosphamide-resistant proliferative lupus nephritis in the fourth criteria from renal biopsy, as well as to determine the economic evaluation of enteric-coated Mycophenolate Sodium compared to the treatment with standard intravenous cyclophosphamide in a health security perspective and a social perspective  

Documents

Activity

โครงการประเมินเทคโนโลยีและนโยบายด้านสุขภาพ ชั้น 6 อาคาร 6 กรมอนามัย กระทรวงสาธารณสุข ถ.ติวานนท์ อ.เมือง จ.นนทบุรี 11000

โทร : +662-590-4549 , +662-590-4374-5
โทรสาร : +662-590-4369
E-mail : [email protected]

© Copyright - HITAP 2014
Top